Medpace Holdings, Inc. (MEDP)
NASDAQ: MEDP · Real-Time Price · USD
576.49
-7.21 (-1.24%)
At close: Dec 3, 2025, 4:00 PM EST
577.00
+0.51 (0.09%)
Pre-market: Dec 4, 2025, 7:04 AM EST
Medpace Holdings Revenue
Medpace Holdings had revenue of $659.90M in the quarter ending September 30, 2025, with 23.74% growth. This brings the company's revenue in the last twelve months to $2.36B, up 13.88% year-over-year. In the year 2024, Medpace Holdings had annual revenue of $2.11B with 11.84% growth.
Revenue (ttm)
$2.36B
Revenue Growth
+13.88%
P/S Ratio
7.21
Revenue / Employee
$399,724
Employees
5,900
Market Cap
16.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.11B | 223.21M | 11.84% |
| Dec 31, 2023 | 1.89B | 425.85M | 29.17% |
| Dec 31, 2022 | 1.46B | 317.62M | 27.80% |
| Dec 31, 2021 | 1.14B | 216.45M | 23.38% |
| Dec 31, 2020 | 925.93M | 64.96M | 7.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MEDP News
- 6 days ago - Wasatch Global Opportunities Fund Q3 2025 Contributors And Detractors - Seeking Alpha
- 15 days ago - 6 Healthcare Stocks With Strong Upward Momentum - Benzinga
- 5 weeks ago - Why Medpace Popped 13% This Week - The Motley Fool
- 5 weeks ago - Medpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings - Benzinga
- 5 weeks ago - Medpace: Full CRO Model Builds Net Revenue Growth, Maintain At Strong Buy - Seeking Alpha
- 5 weeks ago - Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins - Benzinga
- 5 weeks ago - Medpace Holdings' Good Quarter Is Another Sign Biotech Is Back - Barrons